Lexaria Announces Results from Animal Study GLP-1-A26-1
Key Highlights
- ➤Lexaria filed three patent applications covering new formulations evaluated in the animal study
- ➤DHT-CBD ALT2 delivered 566% higher mean brain absorption than REF at eight hours
- ➤DHT-CBD ALT1 achieved highest dose-adjusted plasma absorption among tested alternative formulations
- ➤DHT-SEMA ALT2 was the strongest alternative, but plasma absorption remained below REF
- ➤Study tested 11 formulations in Sprague-Dawley rats targeting SNAC alternatives for oral GLP-1 delivery
Expert Statements
Rich Christopher, CEO of Lexaria Bioscience Corp.
“We are delighted that certain new formulations in this Study achieved our highest-ever DehydraTECH pharmaceutical-grade relative absorption performance,”
Rich Christopher, CEO of Lexaria Bioscience Corp.
“These new formulation enhancements should enable Lexaria to achieve even greater performance in the future and help us to stay ahead of competitive oral delivery developments in 2027 and beyond.”
KELOWNA, BC / ACCESS Newswire / October 15, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide the following results from animal study GLP-1-A26-1 (the "Study") that evaluated a number of formulation enhancements using both DehydraTECH-CBD ("DHT-CBD") compositions and DehydraTECH-semaglutide ("DHT-SEMA") glucagon-like peptide-1 ("GLP-1") compositions to explore the potential for additional improved performance, as well as stake new intellectual property ("IP") claims.
Lexaria has already filed 3 new patent applications related to the formulations evaluated in this Study to protect this new IP. As these patent applications are not yet published, we will not be providing full details of all the specific formulations or outcomes at this time.
Get started
Create a free account to read the full story.